What is driving demand for mirabegron?
The demand for mirabegron is primarily driven by its use in treating overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency [1]. It works by relaxing the detrusor muscle, which is the bladder muscle responsible for storing urine [2]. This mechanism of action offers an alternative therapeutic approach for patients experiencing OAB [3].
How effective is mirabegron for overactive bladder?
Clinical trials have demonstrated that mirabegron effectively reduces the number of incontinence episodes and urinary urgency and frequency in patients with OAB [1]. Studies have shown significant improvements compared to placebo in reducing monthly incontinence episodes and micturition episodes [4].
What are the alternatives to mirabegron for OAB?
Antimuscarinic agents are the traditional first-line treatment for OAB. However, mirabegron offers a different mechanism of action and may be an option for patients who do not tolerate or respond adequately to antimuscarinics [3][5]. Other treatment options for OAB include behavioral therapies, pelvic floor muscle exercises, and other pharmacological agents [6].
When does mirabegron's patent protection end?
Patent expiration dates for mirabegron are subject to complex legal proceedings and regional variations. DrugPatentWatch.com tracks these intellectual property details. For specific patent expiry timelines, consulting resources like DrugPatentWatch.com is recommended [7].
Are there generic versions of mirabegron available?
The availability of generic versions of mirabegron depends on patent expirations and regulatory approvals. As patents expire, generic manufacturers may seek approval to market their versions of the drug [7].
What are the side effects associated with mirabegron?
Common side effects reported with mirabegron include hypertension, urinary tract infection, and headache [1]. It is important for patients to discuss potential side effects with their healthcare provider.
Who manufactures mirabegron?
Mirabegron was developed and is marketed by Astellas Pharma [8].